Probiotic Strains for Gut Repair

The probiotic supplement market is dominated by generic multi-strain formulations marketed for general gut health, but the clinical evidence is not generic — it is strain-specific. The differences between two Lactobacillus rhamnosus strains can be larger than the differences between Lactobacillus and Bifidobacterium. The clinical literature has identified a small number of specific strains with strong evidence for specific indications: Lactobacillus rhamnosus GG (the ATCC 53103 strain isolated by Gorbach and Goldin) for antibiotic-associated diarrhea (significant in children) and acute diarrhea (where the newest large studies found no benefit), Saccharomyces boulardii CNCM I-745 (the only commercial yeast probiotic) for Clostridioides difficile and traveler's diarrhea, a high-dose 8-strain mixture for ulcerative colitis and pouchitis, and Bifidobacterium longum 35624 for irritable bowel syndrome (IBS). This deep-dive walks through the strain-by-strain evidence base, the practical colony-forming unit (CFU) dosing, the post-antibiotic recolonization window, the contraindications in immunocompromise, and the distinction between probiotic supplements and fermented foods.

Table of Contents

  1. Why Strain-Specific Evidence Matters
  2. Lactobacillus rhamnosus GG (LGG)
  3. Saccharomyces boulardii CNCM I-745
  4. The High-Dose Eight-Strain Mixture
  5. Bifidobacterium longum 35624
  6. Other Strains with Meaningful Evidence
  7. CFU Dosing and Practical Use
  8. The Post-Antibiotic Recolonization Window
  9. Fermented Foods vs Probiotic Supplements
  10. Cautions and Contraindications
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Why Strain-Specific Evidence Matters

Bacterial taxonomy is hierarchical: genus → species → strain. A bacterial strain is a specific isolate of a species with a characterized genome and phenotype, typically identified by alphanumeric designation (e.g., GG, 35624, NCFM, BB-12). The differences between strains of the same species can be enormous — gene content can vary by 20-30% between strains, and clinical effects vary correspondingly.

The International Scientific Association for Probiotics and Prebiotics (ISAPP) defines probiotics as "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host." The "adequate amounts" and "health benefit" are both strain-specific. A claim like "Lactobacillus acidophilus is good for digestion" is scientifically empty — the meaningful claim is "L. acidophilus NCFM at 10 billion CFU/day reduced bloating in patients with functional dyspepsia in trial X."

What this means when reading a probiotic label:

The names themselves changed in 2020. Scientists who compared whole genomes split the old genus Lactobacillus into 25 genera, including new genera named Lacticaseibacillus and Lactiplantibacillus; under the new names L. rhamnosus GG is Lacticaseibacillus rhamnosus GG and L. plantarum is Lactiplantibacillus plantarum. The authors note that the common term “lactobacilli” stays useful for all of these organisms. Labels and studies may use either the old or the new name for the same strain.

Back to Table of Contents

Lactobacillus rhamnosus GG (LGG)

Lactobacillus rhamnosus GG (also designated ATCC 53103) is the most extensively studied probiotic strain in the world — over 1,000 published trials and observational studies. The strain was isolated in 1985 by Sherwood Gorbach and Barry Goldin at Tufts University (the "GG" stands for Gorbach-Goldin) from the gastrointestinal tract of a healthy human volunteer.

The major LGG indications studied:

What the newest acute-diarrhea studies found. In 2018 a U.S. trial in 10 children's emergency departments gave 971 children aged 3 months to 4 years with stomach flu (acute gastroenteritis) a 5-day course of LGG (10 billion CFU twice daily) or a matching placebo. Moderate-to-severe illness occurred in 11.8% of the LGG group and 12.6% of the placebo group, and diarrhea lasted a median of 49.7 hours versus 50.9 hours — no meaningful difference. The 2020 Cochrane review pooled 82 studies with 12,127 people (almost all children). In the trials at low risk of bias, probiotics made no difference to the chance of diarrhea lasting 48 hours or more (risk ratio 1.00), and the reviewers found evidence of publication bias; analyses limited to LGG or S. boulardii gave similar results, with results varying widely between trials.

The dose used in most clinical trials is 10-20 billion CFU per day, typically as one or two divided doses. LGG is acid-stable and bile-stable, surviving stomach passage well. It does not permanently colonize the gut — transit time studies show it disappears from stool within 1-2 weeks of discontinuation. The clinical effect is therefore dependent on continuous administration.

Commercial forms: LGG is sold over the counter as a single-strain product and appears in many multi-strain formulations.

Back to Table of Contents

Saccharomyces boulardii CNCM I-745

Saccharomyces boulardii is the only yeast probiotic with rigorous clinical evidence. It was isolated in 1923 by French microbiologist Henri Boulard from lychee fruit in Indochina (now Vietnam), after he observed that the local population brewed a lychee tea to treat cholera-related diarrhea. The CNCM I-745 strain (sold in the US under many product names) is the strain with the published clinical evidence base.

Because S. boulardii is a yeast rather than a bacterium, it is intrinsically resistant to antibacterial antibiotics — which is why it is studied alongside antibiotic courses: the antibiotic does not kill it. Its mechanism is multifactorial: it secretes a 54 kDa protease that cleaves Clostridioides difficile toxin A, it stimulates secretory immunoglobulin A (IgA) production, it competitively inhibits adhesion of pathogenic bacteria, and it stimulates short-chain fatty acid production by other commensals.

Major indications with strong evidence:

Dosing: typical clinical dose is 250-500 mg twice daily (one 250 mg capsule contains approximately 5 billion CFU). For C. difficile prevention alongside antibiotics, practitioners describe starting it with the first antibiotic dose and continuing for 1 week after the course ends.

Back to Table of Contents

The High-Dose Eight-Strain Mixture

This high-dose 8-strain mixture contains eight bacterial strains: four Lactobacillus (L. plantarum, L. paracasei, L. acidophilus, L. delbrueckii subsp. bulgaricus), three Bifidobacterium (B. breve, B. longum, B. infantis), and one Streptococcus (S. thermophilus). Total CFU is 450 billion per sachet (the prescription-strength version) or 112.5 billion per capsule (the consumer-grade version).

The history is complicated. The original formulation was developed by Italian gastroenterologist Claudio De Simone. Since 2016 the original eight-strain high-dose probiotic mixture and a later reformulation have been sold in North America under different product names, and the two are not documented to contain identical strains. The published clinical results below come from the original mixture.

Major indications with strong evidence:

Dosing: in active ulcerative colitis, the trial dosing is 900 billion CFU per day (2 sachets twice daily). For maintenance, 450 billion CFU per day. For pouchitis maintenance, 450-900 billion CFU per day. These doses are far higher than typical over-the-counter (OTC) probiotics, which is part of the clinical efficacy story — the high CFU saturates the colon and produces measurable changes in fecal short-chain fatty acid production.

Back to Table of Contents

Bifidobacterium longum 35624

Bifidobacterium longum 35624 is the strain with the strongest irritable bowel syndrome evidence in any monostrain formulation. It was developed at the Alimentary Pharmabiotic Centre at University College Cork by Eamonn Quigley and colleagues, originally isolated from a healthy human gastrointestinal tract. The Whorwell et al. 2006 trial published in American Journal of Gastroenterology randomized 362 women with irritable bowel syndrome to one of three doses of B. infantis 35624 (later reclassified as B. longum 35624 after taxonomic revision) or placebo for 4 weeks. Only the middle dose, 100 million (1 × 108) CFU, was significantly better than placebo for abdominal pain or discomfort, bloating, bowel dysfunction and the composite symptom score; the lowest and highest doses (1 million and 10 billion CFU) were not significantly different from placebo, and the highest dose had formulation problems.

Subsequent studies have confirmed the effect and identified the likely mechanism: B. longum 35624 reduces pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-6 and interleukin-1) and increases regulatory cytokines (interleukin-10), shifting the gut immune set-point toward tolerance.

Commercial form: sold over the counter in the US as a single-strain capsule. The labeled dose is 1 billion CFU per capsule, taken once daily. Onset of clinical effect typically requires 4-6 weeks of daily use.

Indications:

Back to Table of Contents

Other Strains with Meaningful Evidence

Back to Table of Contents

CFU Dosing and Practical Use

Clinical trial CFU dosing varies enormously by strain and indication:

Practical timing: most probiotics are described as surviving better when taken with food (the buffering effect of food on stomach acid increases survival through stomach passage). Exception: S. boulardii, which is intrinsically acid-stable and can be taken any time. For high-CFU multi-strain formulations, splitting the daily dose into 2-3 administrations may improve colonization saturation.

CFU degradation between manufacture and consumption is the biggest source of over-the-counter probiotic underdosing. Many products are labeled at manufacture CFU; by the time of consumption (after warehouse, shipping, retail storage, home storage), actual CFU may be 10-50% of label. Labels stating "CFU guaranteed through expiration date", with clearly stated refrigeration requirements, are the ones that address this gap.

Back to Table of Contents

The Post-Antibiotic Recolonization Window

Antibiotics reduce gut microbial diversity dramatically — broad-spectrum antibiotic courses (clindamycin, cephalosporins, fluoroquinolones) can reduce gut bacterial CFU by 2-3 log within days. Recovery is partial and often incomplete: trials of stool microbiome 6 months after a single antibiotic course typically show persistent loss of approximately 10-20% of the pre-antibiotic species, with the lost organisms not returning even at 1 year follow-up.

The post-antibiotic period is therefore both a window of risk (dysbiosis, C. difficile susceptibility, opportunistic overgrowth) and a window of opportunity (the relatively empty niche may be more receptive to colonization by deliberately introduced strains). A regimen commonly described in practice (no guideline is cited for it, and the 2018 study below found that probiotics after antibiotics slowed the gut's own recovery):

What a 2018 study found about probiotics after antibiotics. Researchers at the Weizmann Institute examined the gut lining directly, in mice and in people, after a course of antibiotics. Compared with recovering on their own, those given a multi-strain probiotic had a markedly delayed and persistently incomplete return of their own gut bacteria, in stool and in the gut lining. Putting back the person's own stool collected before the antibiotics (autologous fecal microbiota transplantation) gave a rapid, near-complete recovery within days. In laboratory tests, substances released by Lactobacillus helped explain the slowed recovery. The authors conclude that possible benefits of probiotics after antibiotics may be offset by this slower recovery.

An emerging research area is autologous fecal microbiota transplantation (FMT) — storing one's own stool before a planned antibiotic course (e.g., before elective surgery, chemotherapy) and reinstating it afterward via colonoscopy. Early trial evidence (Taur et al. 2018, Suez et al. 2018) supports this approach for restoring pre-antibiotic microbiome composition, but autologous FMT is not yet commercially available outside research settings.

Back to Table of Contents

Fermented Foods vs Probiotic Supplements

Fermented foods (sauerkraut, kimchi, kefir, yogurt, kombucha, miso, natto, tempeh) and probiotic supplements are complementary, not interchangeable.

Probiotic supplements:

Fermented foods:

The two play different roles in the research: daily fermented foods (1-2 servings of properly fermented sauerkraut, kimchi, kefir, or yogurt) for diversity, and targeted probiotic strains matched to a specific indication (LGG for AAD, S. boulardii alongside antibiotics, the eight-strain mixture for ulcerative colitis, B. longum 35624 for irritable bowel syndrome, etc.).

Back to Table of Contents

Cautions and Contraindications

Back to Table of Contents

Key Research Papers

  1. Szajewska H, Kołodziej M (2015). Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. — PubMed PMID: 26365389
  2. McFarland LV (2010). Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. — PubMed PMID: 20458757
  3. Gionchetti P et al. (2000). Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. — PubMed PMID: 10930365
  4. Tursi A et al. (2010). Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment. Am J Gastroenterol. — PubMed
  5. Whorwell PJ et al. (2006). Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. — PubMed PMID: 16863564
  6. Goldenberg JZ et al. (2017). Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database. — PubMed PMID: 29257353
  7. Hill C et al. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. — PubMed
  8. Suez J et al. (2018). Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. — PubMed PMID: 30193113
  9. Wastyk HC et al. (2021). Gut-microbiota-targeted diets modulate human immune status. Cell. — PubMed PMID: 34256014
  10. Besselink MG et al. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial (PROPATRIA). Lancet. An Expression of Concern was published in Lancet 2010;375(9718):875-6. — PubMed PMID: 18279948
  11. Doron S, Snydman DR (2015). Risk and safety of probiotics. Clin Infect Dis. — PubMed
  12. Schnadower D et al. (2018). Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children. N Engl J Med. — PubMed PMID: 30462938
  13. Collinson S, Deans A, Padua-Zamora A, Gregorio GV, Li C, Dans LF, Allen SJ (2020). Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. — PubMed PMID: 33295643
  14. Vinayagamoorthy K, Pentapati KC, Prakash H (2023). Epidemiology of Saccharomyces fungemia: A systematic review. Med Mycol. — PubMed PMID: 36806741
  15. Zheng J et al. (2020). A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol. — PubMed PMID: 32293557
  16. Miele E et al. (2009). Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. — PubMed

PubMed Topic Searches

  1. PubMed: LGG clinical trials
  2. PubMed: S. boulardii and C. difficile
  3. PubMed: eight-strain mixture trials in UC and pouchitis
  4. PubMed: B. longum 35624 for IBS
  5. PubMed: Fermented foods and immune function

Back to Table of Contents

Connections

Back to Table of Contents